Compare NEA & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NEA | IRTC |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.7B |
| IPO Year | 2002 | 2016 |
| Metric | NEA | IRTC |
|---|---|---|
| Price | $11.23 | $109.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $197.92 |
| AVG Volume (30 Days) | ★ 724.6K | 558.1K |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $747,138,000.00 |
| Revenue This Year | N/A | $19.60 |
| Revenue Next Year | N/A | $15.94 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 26.24 |
| 52 Week Low | $10.68 | $100.85 |
| 52 Week High | $11.90 | $210.01 |
| Indicator | NEA | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 30.25 | 42.72 |
| Support Level | $11.04 | $101.30 |
| Resistance Level | $11.70 | $121.88 |
| Average True Range (ATR) | 0.09 | 5.08 |
| MACD | -0.05 | -1.32 |
| Stochastic Oscillator | 2.75 | 15.50 |
Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities. The company invest in Transportation, Utilities, Healthcare, Education and Civics, and other sectors, with maximum investment in Transportation.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.